118 results about "Botulinum toxin type C" patented technology

Media and processes for the fermentation of Clostridium botulinum and obtaining a botulinum toxin for use in formulating botulinum toxin pharmaceutical compositions. The growth media can contain significantly reduced levels of meat or dairy by-products using non-animal based products to replace the animal-derived products. Preferably, the media used are substantially free of animal derived products.

This invention relates to isolated Clostridium botulinum propeptides and neurotoxins, isolated nucleic acid molecules encoding Clostridium botulinum propeptides and neurotoxins, methods of expression, treatment methods, and methods of detecting neurotoxin trafficking. The isolated Clostridium botulinum propeptides have a light chain region; a heavy chain region, where the light and heavy chain regions are linked by a disulfide bond; an intermediate region connecting the light and heavy chain regions and comprising a highly specific protease cleavage site; and an S6 peptide sequence according to SEQ ID NO:2 positioned upstream from, but not attached directly to, the N-terminus of the neurotoxin propeptide at the light chain region to enable site specific attachment of cargo.

The Rho family GTPases regulates axon growth and regeneration. Inactivation of Rho with C3, a toxin from Clostridium botulinum, can stimulate regeneration and sprouting of injured axons. The present invention provides novel chimeric C3-like Rho antagonists. These new antagonists are a significant improvement over C3 compounds because they are 3-4 orders of magnitude more potent to stimulate axon growth on inhibitory substrates than recombinant C3. The invention further provides evidence that these compounds promote repair when applied to the injured mammalian central nervous system.

The present invention relates to methods for treating diseases and disorders by administering a composition containing the neurotoxic component of a Clostridium botulinum toxin complex, wherein the composition is devoid of any other protein of the Clostridium botulinum toxin complex and wherein the composition is administered at short intervals and/or in high doses.

A weak organic acid is used to effect the release of CaDPA from Bacillus or Clostridium endospores, rapidly and at room temperature, to enable detection and measurement of DPA and thereby the assessment of risk associated with exposure to Bacillus anthracis, Clostridium botulinum, and like spores. The method can be applied to airborne, food-borne, and water-borne spores, as well as to spores collected from surfaces or contained in body fluids, and analysis is advantageously carried out using surface-enhanced Raman spectroscopy.

The invention relates to a water-free bio-toilet. A toilet bowl is arranged in the bio-toilet, a bio-reactor communicated with the toilet bowl is arranged below the toilet bowl, the bottom of the bio-reactor is filled with biological stuffing and biological degrading bacteria, and the biological degrading bacteria are special compound bacteria composed of a variety of bacteria and at least comprise enterococcus faecalis, staphylococcus xylose, sporocytophaga, fusarium species, bacillus licheniformis and clostridium botulinum; the bio-reactor is further internally provided with a stirring device, a ventilation device and a temperature control device so that the environment facilitating the degradation reaction can be provided. The water-free bio-toilet has the advantages that water is not additionally required when the water-free bio-toilet is used, water needed for biological degradation comes from excrement and urine of people, all the treating process is carried out in the bio-reactor, no excrement is discharged or leaked externally, no rancid smell is produced in the degradation process, and the biological stuffing which loses effect contains a lot of nutrients such as nitrogen and phosphorus and can be used as organic fertilizer.

The invention relates to fragments of Clostridium botulinum HC that can be linked with an entity (e.g., an antigen, a particle, or a radionuclide) and used to deliver the entity across a non-keratinized epithelial membrane of an animal. The fragments are useful, for example, for making vaccines, antidotes, and anti-toxins and in situations in which rapid uptake of an agent by an animal is desired.

The invention provides potent quinolinol-based BoNT/A small-molecule inhibitors of botulinum neurotoxins, in particular of Clostridium botulinum serotype A neurotoxins. The invention also provides methods of using these small-molecule inhibitors to inhibit infections by Clostridium botulinum, as well as, methods of preventing infections by Clostridium botulinum through materials that may be ingested.

This invention broadly relates to recombinant DNA technology, molecular biology, neuroscience, and medicine. Particularly, the present invention features novel sequences of the toxin and non-toxin components of the Clostridium botulinum toxin type A-Hall (Allergan) strain complex as well as the expression vector system in a heterologous organism and methods to express such nucleic acid sequences.

A preassembled kit organizes the administration of therapeutic botulinum toxin by providing all of the important ingredients necessary for the procedure, including a vial of botulinum toxin preserved on dry ice. The kit also includes saline solution sufficient to dilute the botulinum toxin; a syringe to inject the saline solution into the vial of botulinum toxin; one or more needles to administer the diluted botulinum toxin; and other items associated with the procedure. Such items may include a plurality of absorbent pads, a patient gown, and clinician gloves. Particularly for use in the administration of therapeutic botulinum toxin, the kit may further include at least one radiolucent electrode, and at least one needle adapted for connection to a nerve stimulator.

The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

New transport protein (A) obtained by modification of the heavy chain of a neurotoxin produced by Clostridium botulinum. Compared with the native neurotoxin (nNT) it: (a) binds with higher or lower affinity to nerve cells; (b) has higher/lower neurotoxicity, particularly as determined in the hemidiaphragm assay; and/or (c) has lower affinity for neutralizing antibodies. Independent claims are also included for the following: (1) composition (C) comprising (A) and at least one intervening compound; (2) method for producing (A) or (C) by standard recombinant methods; (3) host cells that contain a recombinant expression vector (EV) encoding (A) or (C); and (4) EV. - ACTIVITY : Relaxant; Antimigraine; Analgesic; Vulnerary; Antidepressant; Virucide. No details of tests for these activities are given. - MECHANISM OF ACTION : Delivering agents that inhibit release of neurotransmitters.

The invention discloses a compound preservative special for a meat product, belonging to the technical field of the processing of the meat product. The compound preservative special for the meat product comprises 0.02-0.06% of sodium diacetate, 0.3-0.5% of sodium lactate, 0.01-0.05% of nisin and 1.0-2.0% of caramel, wherein each component is proportioned by the weight percent occupying the meat product. The invention is applied to the corrosion prevention and the freshness preservation of the meat product, can effectively suppress and kill the nutritive cells and spores of various Gram positive bacteria, such as bacillus stearothermophilus, bacillus cereus, staphyiococcus aureus, Liszt bacteria, clostridium botulinum and the like, greatly lowers the sterilization temperature of the food, shortens the sterilization time of the food, enables the food to keep the original nutritional ingredients, taste and colour and can also save a large amount of energy. The invention has convenient use, is safe and reliable, effectively prolongs the storage period of the product and has good effect of freshness preservation.

The invention provides a method and kit for detecting multiple high-pathogenicity pathogenic bacteria, particularly a method for simultaneously detecting multiple high-pathogenicity pathogenic bacteria, which comprises the following steps: in a polymerase reaction system, carrying out PCR (polymerase chain reaction) on high-pathogenicity pathogenic bacteria by using a specific primer set, thereby obtaining an amplification product; and detecting with a specific probe or probe microsphere. The invention also provides a corresponding kit. The invention can sensitively and conveniently detect and identify multiple high-pathogenicity pathogenic bacteria, including Bacillus anthracis, Yersinia pestis, Clostridium botulinum, Brucella, Streptococcus suis, Vibrio cholerae, Francisella tularensis, Pseudomonas mallei (or Pseudomonas pseudomallei), Coxiella burnetii and Legionella pneumophila.